NCT06823375View on ClinicalTrials.gov

SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 10, 2025

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2028

Conditions
HCC
Interventions
RADIATION

Radiotherapy

\- SBRT 27.5Gy to 50Gy in 5 fractions on alternate days will be delivered between cycle 3 and 5 to the PVTT and its adjacent lesions.

DRUG

Atezolizumab plus Bevacizumab

\- Atezolizumab 1200mg IV and Bevacizumab 15mg/kg IV will be given every 3 weeks, till disease progression, intolerable toxicity, death or withdrawal of consent.

Trial Locations (2)

Unknown

RECRUITING

Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong

NOT_YET_RECRUITING

Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong

All Listed Sponsors
lead

Chinese University of Hong Kong

OTHER

NCT06823375 - SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis | Biotech Hunter | Biotech Hunter